A Phase 1, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 in Patients With Advanced Solid Tumors

15932YL201-INT-101-01-NCT05434234OpenA Phase 1, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 in Patients With Advanced Solid TumorsYL201-INT-101-01NCT05434234IndustrialAdultTreatmentIGlobalLungLiu, StephenGeorgetown University Medical Center : Shannon Raue; Lombardi Comprehensive Cancer Center : Shannon RauePhase IOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS16186Shannon RaueShannon Rauesr1657@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>